Cannabinoids for pain management in rheumatoid arthritis: a scoping review of clinical evidence and mechanisms. (PubMed, Rheumatol Int) - Oct 6, 2026 - "In the randomized trial of 58 patients, nabiximols reduced pain on movement by 0.95 points (p = 0.044), pain at rest by 1.04 points (p = 0.018), and improved sleep quality by 1.17 points (p = 0.027); DAS28 decreased by 0.76 points (p = 0.002), while no serious adverse events were reported...Current clinical evidence remains insufficient to establish the efficacy or long-term safety of cannabinoids for RA-related pain. Larger, rigorously designed trials using standardized cannabinoid formulations and pain-relevant outcomes are needed."
Journal • Review • Immunology • Inflammation • Inflammatory Arthritis • Pain • Rheumatoid Arthritis • Rheumatology
|
|
Agathi Karakosta; Eleni Arnaoutoglou; Georgia Micha; Georgios Stefanakis; Nikolaos Zintziovas; Paraskevi Voulgari; Petros Tzimas
|